Medindia

X

Heterologous Prime/Boost Regimens Evaluated in Preventative HIV Vaccination

by Kathy Jones on  October 2, 2014 at 11:53 PM AIDS/HIV News   - G J E 4
Official data suggests that nearly 40 million people worldwide live with HIV/AIDS, with an estimated 2.5 million new cases per year.
 Heterologous Prime/Boost Regimens Evaluated in Preventative HIV Vaccination
Heterologous Prime/Boost Regimens Evaluated in Preventative HIV Vaccination
Advertisement

Therefore, there has been a large global effort to develop an effective vaccine against the virus. HIV-1 vaccine development has been challenging but recent clinical trials have been promising. A new study in the Journal of Clinical Investigation discusses the results from a clinical trial that evaluated the immune response following different HIV vaccine regimes.

Advertisement
Nicole Frahm and colleagues tested prime-boost regimes combining a New York vaccinia HIV clade B (NYVAC-B) vaccine and a recombinant adenovirus 5-vectored (rAd5-vectored) vaccine in a cohort of healthy volunteers. Individuals that received the rAd5-vectored vaccine followed by the NYVAC-B vaccine exhibited the strongest anti-HIV immune responses. A regime in which individuals received the NYVAC-B vaccine prior to the rAd5-vectored vaccine was not as effective. The results from this study will be important for the design of further clinical trials to evaluate potential HIV-1 vaccine regimes.



Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All